Products
Pre-made Gancotamab benchmark antibody ( scFv, anti-ERBB2/HER2 therapeutic antibody, Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-230
Pre-Made Gancotamab biosimilar, scFv, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Gancotamab, an antibody directed nanotherapeutic that encapsulates doxorubicin in a HER2-targeted liposome, that was being developed by Merrimack.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-ab-230-1mg | 1mg | 3090 | ||
| GMP-Bios-ab-230-10mg | 10mg | Inquiry | ||
| GMP-Bios-ab-230-100mg | 100mg | Inquiry | ||
| GMP-Bios-ab-230-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Gancotamab biosimilar, scFv, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody |
| INN Name | Gancotamab |
| Target | HER2 |
| Format | scFv |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | na |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2018 |
| Year Recommended | 2019 |
| Companies | Merrimack Pharmaceuticals;HERMES BioSciences |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Breast cancer |
| Development Tech | na |
<